UPADACITINIB by Novartis is (jak) inhibitor. Approved for intolerance to one, more tnf blockers, older with active psoriatic arthritis and 9 more indications.
Drug data last refreshed 9h ago
(JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate…
Worked on UPADACITINIB at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis